comparemela.com

Latest Breaking News On - Nmcspc - Page 1 : comparemela.com

Dr Gong on the EMBARK Trial Investigating Enzalutamide in nmCSPC

Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies, which he notes are vital for moving the paradigm forward and ultimately improving patient outcomes.

Enzalutamide Intensifies the Activity of ADT Monotherapy and Expands Limited nmCSPC Treatment Armamentarium

Neal Shore, MD, FACS, highlights the efficacy data from the EMBARK study, toxicities observed with enzalutamide alone or in combination with a LHRH agonist, and the significance of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.